Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
INmune Bio, Inc. (INMB) had Consolidated Net Income/Loss of $-5.41M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-5.41M |
|
-- |
|
-- |
|
$5.81M |
|
$-5.81M |
|
$0.41M |
|
$-5.41M |
|
$-5.41M |
|
$-5.41M |
|
$-5.41M |
|
|
Consolidated Net Income/Loss |
$-5.41M |
$-5.41M |
|
$-5.81M |
|
$-5.76M |
|
26.59M |
|
26.59M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$22.82M |
|
$0.90M |
|
$3.00M |
|
$25.82M |
|
$5.39M |
|
-- |
|
$0.81M |
|
$6.19M |
|
$19.62M |
|
$19.62M |
|
$19.62M |
|
26.59M |
|
| Cash Flow Statement Financials | |
$-3.40M |
|
-- |
|
-- |
|
$24.75M |
|
$21.36M |
|
$-3.39M |
|
$1.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.40M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-27.55% |
|
-27.55% |
|
-20.94% |
|
-27.55% |
|
$0.74 |
|
$-0.13 |
|
$-0.13 |
|